Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4+ and CD8+ T Cells

American Journal of Transplantation

Volumn 9, Issue 12, 2009, Pages 2727-2735

  Monti, P ^a,b   Brigatti, C ^a   Heninger, A K ^b   Scirpoli, M ^a   Bonifacio, E ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Immunosuppression; T cell; Transplant; Zenapax

Indexed keywords

DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; STAT5 PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOMEOSTASIS; HUMAN; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; RECEPTORS, INTERLEUKIN-7; STAT5 TRANSCRIPTION FACTOR;

EID: 72449208029     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02825.x     Document Type: Article

References (21)

1. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989 86 : 10029 10033.
2. Rickert M, Boulanger MJ, Goriatcheva N, Garcia KC. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors. J Mol Biol 2004 339 : 1115 1128.
3. Goebel J, Stevens E, Forrest K, Roszman TL. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl Immunol 2000 8 : 153 159.
4. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998 338 : 161 165.
5. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995 155 : 489 498.
6. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998 161 : 1659 1663.
7. Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol 2008 26 : 5735 5741.
8. Codarri L, Vallotton L, Ciuffreda D, Venetz JP, Garcia M, Hadaya K et al. Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL- 7Ralphahigh cell population in solid organ transplant recipients. J Exp Med 2007 204 : 1533 1541.
9. Monti P, Scirpoli M, Maffi P, Ghidoli N, De Taddeo F, Bertuzzi F et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008 118 : 1806 1814.
10. Palmer MJ, Mahajan VS, Trajman LC, Irvine DJ, Lauffenburger DA, Chen J. Interleukin-7 receptor signaling network: An integrated systems perspective. Cell Mol Immunol 2008 5 : 79 89.
11. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000 243 : 147 154.
12. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: Monitoring single cell signaling events. Cytometry A 2003 55 : 61 70.
13. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol 2007 27 : 1 18.
14. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006 203 : 1701 1711.
15. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006 203 : 1693 1700.
16. Chung B, Dudl EP, Min D, Barsky L, Smiley N, Weinberg KI. Prevention of graft-versus-host disease by anti IL-7Ralpha antibody. Blood 2007 110 : 2803 2810.
17. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004 10 : 87 92.
18. Tkaczuk J, Yu CL, Baksh S, Milford EL, Carpenter CB, Burakoff SJ et al. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling. Am J Transplant 2002 2 : 31 40.
19. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006 24 : 657 679.
20. Kim SE. Daclizumab treatment for multiple sclerosis. Pharmacotherapy 2009 29 : 227 235.
21. Imamichi H, Sereti I, Lane HC. IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3. Eur J Immunol 2008 38 : 1621 1630.